Título:	Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia : current perspectives, future challenges, and clinical implications
Autor(es):	Assis, Alan Jhones Barbosa Santana, Brunna Letícia de Oliveira Gualberto, Ana Cristina Moura Silva, Fabio Pittella
Afiliação do autor:	University of Brasília, Faculty of Health Sciences and Medicine, Laboratory of Molecular Pathology of Cancer University of Brasília, Faculty of Health Sciences and Medicine, Laboratory of Molecular Pathology of Cancer University of Brasília, Faculty of Health Sciences and Medicine, Laboratory of Molecular Pathology of Cancer University of Brasília, Faculty of Health Sciences and Medicine, Laboratory of Molecular Pathology of Cancer
Assunto:	CRISPR-Cas9 Genética - estudo e ensino Leucemia linfoblástica aguda (LLA) Terapia celular Câncer - tratamento
Data de publicação:	Dez-2023
Editora:	Frontiers
Referência:	ASSIS, Alan Jhones Barbosa et al. Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications. Frontiers in Pharmacology, [S. l.], v. 14, 1322937, 2023. DOI: https://doi.org/10.3389/fphar.2023.1322937. Disponível em: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1322937/full. Acesso em: 12 maio 2026.
Abstract:	Acute Lymphoblastic Leukemia (ALL) is the predominant hematological malignancy in pediatric populations, originating from B- or T-cell precursors within the bone marrow. The disease exhibits a high degree of heterogeneity, both at the molecular level and in terms of clinical presentation. A complex interplay between inherited and acquired genetic alterations contributes to disease pathogenesis, often resulting in the disruption of cellular functions integral to the leukemogenic process. The advent of CRISPR/Cas9 as a gene editing tool has revolutionized biological research, underscoring its potential to modify specific genomic loci implicated in cancer. Enhanced understanding of molecular alterations in ALL has facilitated significant advancements in therapeutic strategies. In this review, we scrutinize the application of CRISPR/Cas9 as a tool for identifying genetic targets to improve therapy, circumvent drug resistance, and facilitate CAR-T cell-based immunotherapy. Additionally, we discuss the challenges and future prospects of CRISPR/Cas9 applications in ALL.
Unidade Acadêmica:	Faculdade de Ciências da Saúde (FS) Departamento de Farmácia (FS FAR)
Programa de pós-graduação:	Programa de Pós-Graduação em Ciências Farmacêuticas
Licença:	© 2023 Assis, Santana, Gualberto and Pittella-Silva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
DOI:	https://doi.org/10.3389/fphar.2023.1322937
Aparece nas coleções:	Artigos publicados em periódicos e afins

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.